Smith Micro (SMSI) Q2 2026 Earnings Call Transcript

Smith Micro (SMSI) reported Q2 2026 revenue of $4.3M, down 2% YoY but up 3% sequentially. The company expects Q3 revenue of $5.0M-$5.4M, driven by new contracts and product launches. Gross margin improved to 81.3%, and operating expenses decreased significantly. The company anticipates adding resources to support pipeline growth, potentially increasing non-GAAP operating expenses by up to 6% in Q3.

Original reporting
Published Aug 22, 2026, 3:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 3:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Smith Micro (SMSI) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$SMSINeutralMed
01

Why it matters

Earnings release provides fresh guidance and reveals cost‑reduction progress, offering a basis for short‑term trading decisions.

02

Market read

Micro‑cap earnings with modest guidance; relevance mainly to traders focused on small‑cap tech and margin trends.

03

What to watch

Potential upside from pending multi‑year contract extension and new SafePath SDK/API offerings.

Relevance 6/10Novelty 7/10Timing: post‑earnings Q2 2026 release

Background

Smith Micro reported Q2 2026 results, noting a slight revenue decline YoY but strong margin improvement and a reverse stock split.

Company-level read

Ticker impact

$SMSINeutralMedium confidence
Context

Q2 2026 earnings call disclosed revenue of $4.3M, gross margin 81.3%, and guidance for Q3 revenue $5.0M-$5.4M.

Expected impact

Potential modest upside if market values improved margins and Q3 guidance; downside risk if revenue miss concerns persist.

Evidence & confidence

Micro‑cap with low absolute numbers; improved margins may attract value buyers, but revenue decline limits upside.

Market effects

Highlights continued demand for safety software in consumer and enterprise segments.

Limited to U.S. small‑cap tech space.

Low; company is niche with minimal global exposure.

Counterpoint

Margin expansion may be temporary; revenue decline suggests underlying demand weakness.

Key entities

  • Smith Micro

    Provider of safety and security software solutions.

  • Bethany Braund

    Speaker presenting the earnings details.

Related articles

$SMSIMed

Smith Micro Reports Third Quarter 2026 Financial Results

SMITH MICRO SOFTWARE, INC. (SMSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IR INQUIRIES: Charles Messman Investor Relations 412-837-5300 IR@smithmicro.com Smith Micro Reports Third Quarter 2026 Financial Results PITTSBURGH, PA, November 12, 2026 – Smith Micro Software, Inc. ( Nasdaq: SMSI ) (“Smith Micro” or the “Company”) today reported fi

$SMSIMed

Smith Micro Reports Second Quarter 2026 Financial Results

SMITH MICRO SOFTWARE, INC. (SMSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IR INQUIRIES: Charles Messman Investor Relations 412-837-5300 IR@smithmicro.com Smith Micro Reports Second Quarter 2026 Financial Results PITTSBURGH, PA, August 13, 2026 – Smith Micro Software, Inc. ( Nasdaq: SMSI ) (“Smith Micro” or the “Company”) today reported fin

$NOKMed

LightCounting:: November 2026 Nokia SReXperts

Nokia hosted its SReXperts/Wavelengths conference in November 2026, focusing on AI's impact on connectivity and its solutions for customers. The company reported strong Q3 2026 earnings, with AI & Cloud sales doubling year-over-year and $1.7 billion in new orders. Nokia expects 25-30% growth in its Optical and IP Networks businesses in 2027. The company aims to help telecom operators adapt to AI-driven changes and capitalize on new opportunities.

$IBRXLow

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.